Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Exploring an essential biomarker in pulmonary fibrosis: an integrated and cross-disease approach with spatial transcriptomics and single-cell RNA sequencing

ABSTRACT: Exploring an essential biomarker in pulmonary fibrosis: an integrated and cross-disease approach with spatial transcriptomics and single-cell RNA sequencing

PROVIDER: PRJNA1101515 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28685170_1.fastq.gz	Fastqsanger.gz
	SRR28685170_2.fastq.gz	Fastqsanger.gz
	SRR28685172_1.fastq.gz	Fastqsanger.gz
	SRR28685172_2.fastq.gz	Fastqsanger.gz
	SRR28685173_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

Exploring an essential biomarker in pulmonary fibrosis: an integrated and cross-disease approach with spatial transcriptomics and single-cell RNA sequencing (Spatial Transcriptomics, part 2)

Project description:We cross-sectionally examined various interstitial lung diseases (ILDs) via spatial transcriptomics of human samples. We unveiled crucial gene expression patterns and molecules involving fibrosis, exploring prognostic significance of this molecule in unclassifiable ILDs.

2025-06-02 | GSE295619 | GEO

Exploring an essential biomarker in pulmonary fibrosis: an integrated and cross-disease approach with spatial transcriptomics and single-cell RNA sequencing (Spatial Transcriptomics)

Project description:Exploring an essential biomarker in pulmonary fibrosis: an integrated and cross-disease approach with spatial transcriptomics and single-cell RNA sequencing (Spatial Transcriptomics)

| PRJNA1100492 | ENA

Exploring an essential biomarker in pulmonary fibrosis: an integrated and cross-disease approach with spatial transcriptomics and single-cell RNA sequencing (Spatial Transcriptomics, part 2)

| PRJNA1255478 | ENA

Exploring an essential biomarker in pulmonary fibrosis: an integrated and cross-disease approach with spatial transcriptomics and single-cell RNA sequencing

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-06-02 | GSE264233 | GEO

Exploring an essential biomarker in pulmonary fibrosis: an integrated and cross-disease approach with spatial transcriptomics and single-cell RNA sequencing (Spatial Transcriptomics)

Project description:We cross-sectionally examined various interstitial lung diseases (ILDs) via spatial transcriptomics and single-cell RNA-Seq (scRNA-seq) analysis of human samples. We unveiled crucial gene expression patterns and molecules central to fibrosis, establishing prognostic significance of this molecule in unclassifiable ILDs.

2025-06-02 | GSE263976 | GEO

The exosomal CD44 from bronchoalveolar lavage fluid as a biomarker for pulmonary fibrosis in diffuse parenchymal lung diseases

Project description:Diffuse parenchymal lung diseases (DPLD) cover heterogeneous types of lung disorders with a plethora of variously combined clinical manifestations. Among many pathological phenotypes, pulmonary fibrosis is the most devastating. Pulmonary fibrosis is a characteristic sign for idiopathic pulmonary fibrosis (IPF); however, it may occur also in later stages of other types of DPLD. Despite a poor prognosis brought by pulmonary fibrosis, there are no specific diagnostic biomarkers for the initial development of this fatal condition. The major hallmark of lung fibrosis is uncontrolled activation of lung fibroblasts to myofibroblasts associated with extracellular matrix deposition and the loss of both lung structure and function. Here, we used this peculiar feature in order to identify specific biomarkers of pulmonary fibrosis in bronchoalveolar lavage fluids. The primary MRC-5 human fibroblasts were activated with BALF collected from patients with clinically diagnosed lung fibrosis; the activated fibroblasts were then washed rigorously, and further incubated to allow secretion; afterwards, the secretomes were analysed by mass spectrometry. In this way, the CD44 protein was identified. Finally, BALF of all DPLD patients were positively tested for the presence of CD44 by ELISA. Biochemical and biophysical characterizations revealed an exosomal origin of CD44. Correlation studies confirmed the exosomal CD44 in BALF as a specific and reliable biomarker of IPF and other types of DPLD accompanied with pulmonary fibrosis.

2025-01-03 | PXD055250 | Pride

PLASMA biomarkers of Idiopathic Pulmonary Fibrosis

Project description:The aim of the current study is to find plasma-based biomarker candidates for Idiopathic Pulmonary Fibrosis (IPF). Incidence of IPF seems to be increasing in Europe and there is significant mortality associated with IPF. There are no sensistive biomarkers for IPF and diagnosis is entirely clinical and/or histopathological which is often delayed. Minimally invasive biomarkers of IPF would be expected to aid clinicians perfrom early diagnosis of IPF enabling better management of the disease.

2020-05-13 | PXD010965 | Pride

Proximal Pulmonary Artery Stiffening as a Biomarker of Cardiopulmonary Aging

Project description:Proximal Pulmonary Artery Stiffening as a Biomarker of Cardiopulmonary Aging

| PRJNA1273893 | ENA

The cross-talk between TGF-b and periostin can be targeted for pulmonary fibrosis [AR2819]

Project description:Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized as progressive and irreversible fibrosis in the interstitium of lung tissues. There is still an unmet need to develop a novel therapeutic drug for IPF. We have previously demonstrated that periostin, a matricellular protein, plays an important role in the pathogenesis of pulmonary fibrosis. However, the underlying mechanism of how periostin causes pulmonary fibrosis remains unclear. In this study, we sought to see whether the cross-talk between transforming growth factor-b (TGF-b), a central mediator in the pathogenesis of pulmonary fibrosis, and periostin in lung fibroblasts leads to generation of pulmonary fibrosis and whether taking advantage of the cross-talk between TGF-b and periostin, inhibitors for integrin aVb3, a periostin receptor, can block pulmonary fibrosis in the model mice. We found that there exists a cross-talk between TGF-b and periostin signals via aVb3/b5 converging into Smad3. This cross-talk is important for expression of several downstream molecules of TGF-b including serpin family E member 1, CCN family member 2/connective tissue growth factor, insulin-like growth factor binding protein-3, and IL-11, all of which have been already shown to be important for pulmonary fibrosis. We, moreover, found several potent integrin inhibitors to block the cross-talking with TGF-b signals and CP4715, one of the compounds, improved bleomycin-induced pulmonary fibrosis in mice. These results suggest that the cross-talk between TGF-b and periostin can be targeted for pulmonary fibrosis and that CP4715 can be a potential therapeutic agent to block the cross-talk between TGF-b and periostin.

2019-09-17 | GSE124780 | GEO

The cross-talk between TGF-b and periostin can be targeted for pulmonary fibrosis [AR2857]

2019-09-17 | GSE124781 | GEO